Design Therapeutics, Inc. (NASDAQ:DSGN) Director Deepa Prasad Sells 3,806 Shares

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Deepa Prasad sold 3,806 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $6.27, for a total transaction of $23,863.62. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at approximately $125,400. The trade was a 15.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Design Therapeutics Stock Performance

Shares of Design Therapeutics stock opened at $5.99 on Friday. The company has a 50-day simple moving average of $5.88 and a two-hundred day simple moving average of $4.97. The stock has a market capitalization of $339.16 million, a PE ratio of -7.05 and a beta of 1.86. Design Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $7.77.

Hedge Funds Weigh In On Design Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC boosted its stake in Design Therapeutics by 318.8% during the 3rd quarter. Virtu Financial LLC now owns 46,356 shares of the company’s stock valued at $249,000 after purchasing an additional 35,286 shares during the last quarter. Barclays PLC lifted its holdings in shares of Design Therapeutics by 34.2% during the third quarter. Barclays PLC now owns 96,635 shares of the company’s stock valued at $520,000 after purchasing an additional 24,602 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Design Therapeutics by 7.1% during the third quarter. Geode Capital Management LLC now owns 758,550 shares of the company’s stock valued at $4,081,000 after buying an additional 50,579 shares during the last quarter. Frazier Life Sciences Management L.P. increased its holdings in Design Therapeutics by 58.3% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,892,547 shares of the company’s stock worth $10,182,000 after buying an additional 697,368 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its position in Design Therapeutics by 61.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock worth $8,612,000 after buying an additional 609,939 shares during the last quarter. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.